PT  - JOURNAL ARTICLE
AU  - Okurut, Samuel
AU  - Boulware, David R
AU  - Okafor, Elizabeth
AU  - Rhein, Joshua
AU  - Kajumbula, Henry
AU  - Bagaya, Bernard
AU  - Bwanga, Freddie
AU  - Olobo, Joseph O
AU  - Manabe, Yukari C
AU  - Meya, David B
AU  - Janoff, Edward N
AU  - ,
TI  - Divergent Neuroimmune Signatures in the Cerebrospinal Fluid Predict Differential Gender-Specific Survival Among Patients With HIV-Associated Cryptococcal Meningitis
AID  - 10.1101/2023.08.09.23293903
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.09.23293903
4099  - http://medrxiv.org/content/early/2023/08/15/2023.08.09.23293903.short
4100  - http://medrxiv.org/content/early/2023/08/15/2023.08.09.23293903.full
AB  - Survival among people with HIV-associated cryptococcal meningitis (CM) remains low, exceptionally among women with the increased threat of death on current optimal use of antifungal drugs. Cryptococcus dissemination into the central nervous system (CNS) prompts a neuroimmune reaction to activate pathogen concomitant factors. However, no consistent diagnostic or prognostic immune-mediated signature is reported to underpin the risk of death or mechanism to improve treatment or survival. We theorized that the distinct neuroimmune cytokine or chemokine signatures in the cerebrospinal fluid (CSF), distinguish survivors from people who died on antifungal treatment, who may benefit from tailored therapy. We considered the baseline clinical disease features, cryptococcal microbiologic factors, and CSF neuroimmune modulated signatures among 419 consenting adults by gender (biological sex assigned at birth) (168 females and 251 males) by 18 weeks of survival on antifungal management. Survival at 18 weeks was inferior among females than males (47% vs. 59%; hazard ratio HR=1.4, 95% CI: 1.0 to 1.9, and p=0.023). Unsupervised principal component analysis (PCA) demonstrated the divergent neuroimmune signatures by gender, survival, and intragender-specific survival. Overall, females displayed lower levels of PD-L1, IL-1RA, and IL-15 than males (all p≤0.028). Female survivors compared with those who died, expressed significant fold elevations in levels of CSF (CCL11 - myeloid and CXCL10 - lymphoid chemokine (in both p=0.001), and CSF Th1, Th2, and Th17 cytokines. In contrast, male survivors expressed distinctly lower levels of CSF IL-15 and IL-8 compared with those who died. Survivors of either gender demonstrated a significant increase in the levels of immune regulatory element, IL-10. In the finale, we classified divergent neuroimmune key signatures in CSF by gender, survival, and intragender-specific survival among people with HIV-associated cryptococcal meningitis. These intragender-specific survival associated-neuroimmune signatures, suggests the discrete role of gender immune regulating mechanisms as the possible targets for interventions to advance therapy to improve survival among people with HIV-associated cryptococcal meningitis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by funding from the National Institutes of Health and the National Institute of Allergy and Infectious Diseases R01 AI078934, U01 AI089244, R21 NS065713, R01 AI108479, and T32 AI055433 grants to DBM and DRB; R01 AI108479 grant to JR and R01 AI108479 funding to ENJ. National Institute of Neurologic Diseases and Stroke R01 NS086312, R25 TW009345, and K24 AI096925 grant to JR. Fogarty International Center D43 TW009771 grant to YCM and R01 NS086312 grant to RJ. GlaxoSmithKline Trust in Science Africa grant COL 100044928 grant to SO. DELTAS Africa Initiative DEL-15-011 grant to THRiVE-2, DBM. Wellcome Trust grants 107742/Z/15/Z grant to DBM. Veterans Affairs Research Service I01CX001464 grant to ENJ. The Wellcome Trust Training Health Researchers into Vocational Excellence (THRiVE) in East Africa, 087540 grant to DBM. United Kingdom Medical Research Council/Wellcome Trust/Department for International Development (MRC MR/M007413/1 grant to JR and the Grand Challenges Canada S4-0296-01 grant to JR. Funding agencies had no role in study design, data collection, data analysis plan, preparation of the manuscript, or in the decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Infectious Diseases Institute, College of Health Sciences, Makerere University, and Makerere University School of Biomedical Sciences, Higher Degrees Research and Ethics Committee gave waiver of consent and approval to use stored specimens from prior approved studies in the current current.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData is available on request from authors.